Web Results

Boehringer Ingelheim Pharmaceuticals, Inc. | Federal Trade ...

www.ftc.gov/enforcement/cases-proceedings/091-0023/boehringer-ingelheim-pharmaceuticals-inc

Feb 20, 2015 ... application/pdf icon FTC v. Boehringer Ingelheim Pharmaceuticals, Inc. (D.C. Cir. ), Response of FTC to Petition for Rehearing En Banc (113.12 ...

TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC

www.leagle.com/decision/1995235234Conn1_1235/TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

ANUSHAVAN G. TOROSYAN v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. PETERS, C. J. The principal issue in this appeal is whether there was ...

decision - US Court of Appeals

www.cadc.uscourts.gov/internet/opinions.nsf/75189BFE853428D385257DF200543B1F/$file/12-5393-1538477.pdf

Feb 20, 2015 ... Pharmaceuticals, Inc. (“Boehringer”), a brand-name pharmaceutical ... See Boehringer Ingelheim Int'l GmbH v. Barr. Labs. Inc., Civ. Action No. .... omitted); accord 8 CHARLES ALAN WRIGHT ET AL., FEDERAL. PRACTICE ...

2016 District of New Jersey U.S. Federal District Court Case Law ...

law.justia.com/cases/federal/district-courts/new-jersey/njdce/2016/

COOK v. CAMDEN COUNTY DEPARTMENT OF CORRECTIONS et al .... COLEMAN v. ..... BOEHRINGER INGELHEIM PHARMACEUTICALS INC. et al v.

Paper: External Validation of Generic and Cancer-Specific Risk ...

ash.confex.com/ash/2016/webprogram/Paper94926.html

... patients from the general population at low vs. high risk of early (30 day) mortality. Font et al. applied similar risk stratification criteria in a population restricted to ... Disclosures: Coleman: Janssen Pharmaceuticals: Consultancy, Research ... AG: Consultancy, Research Funding; Boehringer-Ingelheim Pharmaceuticals, inc.

Reduced Costs and Length-of-Stay Associated with Rivaroxaban As ...

www.bloodjournal.org/content/128/22/2337

Dec 10, 2016 ... 32.7%) and lower total hospital costs (-$240) vs. parenteral bridging to warfarin ( p²0.03 for all) ... Coleman: Boehringer-Ingelheim Pharmaceuticals, inc. ... Christine Blank, Contributing Editor et al., Formulary Watch , 2016.

In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation

www.law360.com/cases/502983dbe1a1455469000001

Boehringer Ingelheim International GmbH has agreed to pay roughly $650 million to settle claims in multidistrict ... Richard W Cohen, Lowey Dannenberg et al.

American Bar Association - Ballotpedia

ballotpedia.org/American_Bar_Association

Oct 17, 2016 ... A. Schwarzenegger et al. v. M. Plata and R. Coleman, et al. J.D.B. v. State of ... at Austin, et al. Boehringer Ingelheim Pharmaceuticals, Inc. v.

pro se project 2015 year end report - Federal Bar Association

www.fedbar.org/Image-Library/Chapters/Minnesota-Chapter/PRO-SE-PROJECT-2015-YEAR-END-REPORT-.aspx

Jan 8, 2015 ... settled. 35 Eagle Creek Software Services,. Inc. v. Jones et al. (Ron. Sowers), 14- cv-04925-ADM- .... 53 Gillette et al. v Boehringer. Ingelheim Pharmaceuticals Inc. et al., 15-cv-03005-MJD-FLN .... 74 Coleman v. Mpls. Public.

PDF(111K) - Wiley Online Library

onlinelibrary.wiley.com/doi/10.1002/clc.22565/pdf

rivaroxaban vs prior VKA) for ACTS burden and benefit scores were calculated ... Boehringer Ingelheim Pharmaceuticals Inc., Daiichi Sankyo Company, and Portola Pharmaceuticals. .... C. Coleman et al: Rivaroxaban and patient satisfaction.